Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset

被引:291
作者
Gan-Or, Z. [1 ,3 ]
Giladi, N. [2 ,3 ]
Rozovski, U. [1 ]
Shifrin, C. [1 ,2 ,3 ]
Rosner, S. [1 ]
Gurevich, T. [2 ,3 ]
Bar-Shira, A. [1 ]
Orr-Urtreger, A. [1 ,3 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Genet Inst, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Dept Neurol, Parkinson Ctr, Movement Disorders Unit, IL-64239 Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
关键词
D O I
10.1212/01.wnl.0000304039.11891.29
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Mutations in GBA and LRRK2 genes have been implicated in Parkinson disease (PD), particularly in Ashkenazi Jews. Methods: An Israeli Ashkenazi cohort of 420 patients with PD, 333 elderly controls, and 3,805 young controls was screened for eight GBA mutations, which are associated with mild (N370S, R496H) and severe (84GG, IVS2 + 1, V394L, D409H, L444P, RecTL) Gaucher disease. Patients with PD and elderly controls were also genotyped for LRRK2 G2019S. Results: GBA carrier frequency was 17.9% in patients with PD compared to 4.2% in elderly and 6.35% in young controls. The proportion of severe mutation carriers among PD patient GBA carriers was 29% compared to 7% among young controls. Severe and mild GBA mutations increased the risk of developing PD by 13.6- and 2.2-fold, and affected the average age at PD onset (AAO), 55.7 and 57.9 years, compared to 60.7 years in patients without known GBA or LRRK2 mutations. Conclusions: These data demonstrate genotype -phenotype correlations between different GBA mutations and Parkinson disease (PD) risk and AAO in Ashkenazi Jews. Additionally, an earlier AAO was observed in LRRK2 G2019S carrier PD patients. Finally, these data demonstrate that a surprisingly high frequency, more than one third of our patient population, carried a mutation in GBA or LRRK2.
引用
收藏
页码:2277 / 2283
页数:7
相关论文
共 38 条
[1]   Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews [J].
Aharon-Peretz, J ;
Rosenbaum, H ;
Gershoni-Baruch, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1972-1977
[2]   Cross-sectional study of the prevalence of Parkinson's disease in the Kibbutz Movement in Israel [J].
Anca, M ;
Paleacu, D ;
Shabtai, H ;
Giladi, N .
NEUROEPIDEMIOLOGY, 2002, 21 (01) :50-55
[3]   Gaucher's disease with Parkinson's disease - Clinical and pathological aspects [J].
Bembi, B ;
Marsala, SZ ;
Sidransky, E ;
Ciana, G ;
Carrozzi, M ;
Zorzon, M ;
Martini, C ;
Gioulis, M ;
Pittis, MG ;
Capus, L .
NEUROLOGY, 2003, 61 (01) :99-101
[4]   Hematologically important mutations: Gaucher disease [J].
Beutler, E ;
Gelbart, T ;
Scott, CR .
BLOOD CELLS MOLECULES AND DISEASES, 2005, 35 (03) :355-364
[5]  
Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
[6]   The Gaucher registry -: Demographics and disease characteristics of 1698 patients with Gaucher disease [J].
Charrow, J ;
Andersson, HC ;
Kaplan, P ;
Kolodny, EH ;
Mistry, P ;
Pastores, G ;
Rosenbloom, BE ;
Scott, CR ;
Wappner, RS ;
Weinreb, NJ ;
Zimran, A .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (18) :2835-2843
[7]   Frequency of LRRK2 mutations in early- and late-onset Parkinson disease [J].
Clark, L. N. ;
Wang, Y. ;
Karlins, E. ;
Saito, L. ;
Mejia-Santana, H. ;
Harris, J. ;
Louis, E. D. ;
Cote, L. J. ;
Andrews, H. ;
Fahn, S. ;
Waters, C. ;
Ford, B. ;
Frucht, S. ;
Ottman, R. ;
Marder, K. .
NEUROLOGY, 2006, 67 (10) :1786-1791
[8]   Pilot association study of the β-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity [J].
Clark, LN ;
Nicolai, A ;
Afridi, S ;
Harris, J ;
Mejia-Santana, H ;
Strug, L ;
Cote, LJ ;
Louis, ED ;
Andrews, H ;
Waters, C ;
Ford, B ;
Frucht, S ;
Fahn, S ;
Mayeux, R ;
Ottman, R ;
Marder, K .
MOVEMENT DISORDERS, 2005, 20 (01) :100-103
[9]   The biochemistry of Parkinson's disease [J].
Cookson, MR .
ANNUAL REVIEW OF BIOCHEMISTRY, 2005, 74 :29-52
[10]   Parkinson's disease: Mechanisms and models [J].
Dauer, W ;
Przedborski, S .
NEURON, 2003, 39 (06) :889-909